PHASE-II TRIALS OF RHIZOXIN IN ADVANCED OVARIAN, COLORECTAL AND RENAL-CANCER

被引：11

作者：

KERR, DJ

RUSTIN, GJ

KAYE, SB

SELBY, P

BLEEHEN, NM

HARPER, P

BRAMPTON, MH

机构：

[1] CHARING CROSS HOSP,DEPT MED ONCOL,LONDON W6 8RF,ENGLAND

[2] UNIV GLASGOW,CRC,DEPT MED ONCOL,GLASGOW G12 8QQ,LANARK,SCOTLAND

[3] ST JAMES UNIV HOSP,INST CANC STUDIES,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND

[4] UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN ONCOL & RADIOTHERAPY,CAMBRIDGE CB2 2QQ,ENGLAND

[5] GUYS HOSP,LONDON SE1 9RT,ENGLAND

来源：

BRITISH JOURNAL OF CANCER | 1995年 / 72卷 / 05期

关键词：

RHIZOXIN; OVARIAN CANCER; COLORECTAL CANCER; RENAL CANCER;

D O I：

10.1038/bjc.1995.498

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m(-2) every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.

引用

页码：1267 / 1269

页数：3